𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levels of soluble fas/APO-1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis

✍ Scribed by Eckart Knipping; Peter H. Krammer; Karen B. Onel; Thomas J. A. Lehman; Eduardo Mysler; Keith B. Elkon

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
304 KB
Volume
38
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

To quantify soluble Fas/APO-1 (sFas/ APO-1) protein in the serum of patients with systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA).

Methods. Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Disease activity in SLE patients was assessed by the SLE Disease Activity Index.

Results. Increased serum sFas/APO-1 levels were observed in only 1 of the 27 SLE patients (4%) and 3 of the 10 JRA patients (30%).

Conclusion. Increased levels of sFas/APO-1 occurred infrequently in SLE, and the levels were lower than 10 ng/ml. Increased levels of sFas/APO-1 are not specific for SLE. Soluble Fas/APO-1 is unlikely to be of major pathogenetic significance in SLE.

Fas/APO-l/CD95 is a membrane receptor that signals apoptosis in activated mature lymphocytes (1). The Fas pathway is defective in lpr and gld mice (2),

πŸ“œ SIMILAR VOLUMES

The spectrum of apoptotic defects and cl
The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations
✍ Akshay K. Vaishnaw; Elias Toubi; Satomi Ohsako; Jorn Drappa; Saundra Buys; Jaime πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 300 KB πŸ‘ 2 views

## Objective: To determine the clinical spectrum of disease in humans with mutations in the cd95 (fas/ apo-1) receptor and to obtain mechanistic insight into the different clinical phenotypes observed. ## Methods: Clinical information for each of the index cases, first-degree relatives, and any f